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Abstract
Background: Hepatitis C virus (HCV) has been consistently associated to non-Hodgkin lymphoma (NHL); conversely,
few studies have evaluated a comprehensive serological panel of hepatitis B virus (HBV) in NHL etiology.
Methods: We conducted a case-control study in Italy in 1999–2014, enrolling 571 incident, histologically confirmed
NHLs and 1004 cancer-free matched controls. Study subjects provided serum for HCV and HBV testing and for HCV
RNA. Odds ratios (ORs) and corresponding 95 % confidence intervals (CIs) were estimated by logistic regression,
adjusting for potential confounders.
Results: Circulating HCV RNA was detected in 63 (11.1 %) NHL cases and 35 (3.5 %) controls (OR = 3.51, 95 % CI:
2.25–5.47). Chronic HBV infection (i.e., positive to HBV surface antigen - HBsAg+) was found in 3.7 % of cases and
1.7 % of controls (OR = 1.95, 95 % CI: 1.00–3.81); a significantly elevated OR was observed for B-cell NHL (2.11,
95 % CI: 1.07–4.15). People with serological evidence of past HCV or HBV infection, vaccination against HBV, or
detectable antibodies against HBV core antigen (anti-HBc+) alone were not at increased NHL risk.
Conclusions: Our results support a role of chronic HCV infection in NHL in Italy and suggest an involvement of
HBV infection. Associations were clearest for B-cell NHL and diffuse large B-cell lymphoma. Prevention and treatment of
HCV and HBV infection may diminish NHL incidence, notably in areas with high prevalence of hepatitis viruses infection.
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Background
Non-Hodgkin lymphomas (NHLs) are the most frequent
haematological malignancies, representing 3 % of all new
cancer cases worldwide [1]. In Europe, NHLs represented
the 11th most common neoplasm, with around 93,500
new cases diagnosed in 2012. Among European countries,
Italy shows one of the highest age-standardized incidence
rates in both men and women [2].
Although the etiology of most NHL cases is still un-
known, human immunodeficiency virus (HIV) and other
infectious agents such as Epstein-Barr virus, human
herpesvirus 8, human T-lymphotropic virus type I, and
Helicobacter pylori are the best documented causes of
specific types of NHL [3, 4].
Despite the etiologic heterogeneity among NHL sub-
types [5], a consistent association between hepatitis C
virus (HCV) infection and NHL has been well estab-
lished over the last two decades [3, 6, 7], suggesting that,
globally, approximately 8 % of NHL may be attributable
to HCV [8]. Few studies have evaluated the possible role
of hepatitis B virus (HBV) infection as a risk factor for
NHL and showed positive association in some but not
all instances [9]. Furthermore, the majority of these in-
vestigations lacked information on the complete panel of
antigen and antibody markers of HBV infection [10–12].
To further elucidate the relationship between HBV
and HCV infections and the risk of NHLs, we expanded
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a case-control study, which had started in 1999, in different
areas of Italy [13]. Special care was put into exploring a
comprehensive HBV serologic panel to allow a well-defined
assessment of its role in the risk of developing NHL.
Methods
The data in the present study were derived from two con-
secutive case-control studies on lymphomas, conducted
with similar study protocols in the periods 1999–2002
[13] and 2003–2014.
First study, 1999–2002
Between 1999 and 2002, we conducted a multi-cancer
case-control study on the association between HBV/HCV
infections and lymphomas and hepatocellular carcinoma
(HCC) in the province of Pordenone, northeastern Italy,
and the town of Naples, southern Italy. The study design
and findings are described elsewhere [13, 14]. Briefly, the
study included 231 cases with incident, histologically con-
firmed NHL aged 18–84 years (median age: 59 years).
Controls were 547 inpatients aged 18–84 years (median
age: 62 years) admitted for a wide spectrum of acute condi-
tions to the same hospitals as cases. They were frequency-
matched according to center (Pordenone, Naples), gender,
and age (in 5-year age groups) based on the distribution of
overall study cases, which also included Hodgkin lymph-
omas (HL) and HCCs. Consequently, as already reported
[13], controls were younger and more likely to be men
slightly than NHL cases. Specifically excluded from the
control group were patients admitted for malignant dis-
eases, conditions related to alcohol and tobacco consump-
tion or hepatitis viruses as well as any chronic diseases that
might have changed lifestyle habits, hematologic, allergic,
and autoimmune diseases. However, comorbidity for the
above listed diseases was not an exclusion criterion.
Second study, 2003–2014
Between 2003 and 2014, we extended the previous study, fo-
cusing only on lymphomas, and maintaining the same study
design, inclusion and exclusion criteria, and questionnaire.
Cases were 353 patients aged 18–84 years (median age:
56 years) with incident, histologically confirmed NHL. They
were admitted to two National Cancer Institutes located in
Aviano (“Centro di Riferimento Oncologico”) and in Naples
(“Fondazione G. Pascale”), and to the general hospitals lo-
cated in Catania. The control group included 537 patients
aged 18–83 years (median age: 50 years), admitted for a
wide spectrum of acute conditions to the same hospitals as
lymphomas cases. Cases and controls were frequency-
matched by center (Pordenone, Naples, and Catania), gen-
der, and age (in 5-year age groups) based on the distribution
of both HL and NHL cases.
In order to guarantee a sufficient statistical power, par-
ticularly in respect to NHL subtypes and different
combinations of viral markers, the two studies were com-
bined. Overall, a total of 584 NHL cases and 1084 controls
participated in the two studies. Thirteen cases were inter-
viewed but could not give blood samples, leaving 571
NHL cases (median age: 56 years) with available question-
naires and blood samples. Histological diagnoses were
centrally revised, and cases were classified according to
the International Classification of Diseases for Oncology
(third edition) [15]. Blood samples were available for 1004
controls (median age: 57 years) of whom, 20.4 % were ad-
mitted to the hospital for trauma, 39.4 % for nontraumatic
orthopoedic diseases, 20.9 % for acute surgical conditions,
9.2 % for eye diseases, and 10.1 % for a variety of other ill-
nesses. All NHL cases were tested for HIV as part of their
routine management, and they were all HIV-negative. To
the best of our knowledge, no control subjects had a his-
tory of HIV infection or AIDS.
All study participants signed an informed consent, ac-
cording to the recommendations of the Board of Ethics
(CRO Aviano National Cancer Institute Board of Ethics;
National Cancer Institute "G. Pascale" Board of Ethics;
University of Catania Board of Ethics) of each study cen-
ter, which had approved the study.
Questionnaire
Trained interviewers administered a structured ques-
tionnaire to cases and controls during their hospital stay.
It included information on socio-demographic indica-
tors, tobacco smoking, alcohol drinking, dietary habits,
behaviors, major exposures that entailed increased risk
of HCV/HBV transmission and history of diseases affect-
ing the immune system.
HCV and HBV testing
Each case and each control provided a 15 ml blood sample
(7.5 ml in vacutainer tubes with anticoagulant and 7.5 ml
in vacutainer tubes without anticoagulant) the day of
interview (generally the first day of hospital stay). Blood
samples were centrifuged at 1500 g for 10 min, extracted
and distributed into different cryotubes of serum, buffy
coat, and red blood cells, and then stored at −80 °C until
shipment to the laboratory of Microbiology, Immunology
and Virology, National Cancer Institute of Aviano, where
they were tested in a blind fashion.
HCV
Sera were screened for antibodies against HCV (anti-HCV)
using a third-generation chemiluminescent microparticle
immunoassay (CMIA ARCHITECT HCV Ag Assay, Ab-
bott Diagnostic Division, Wiesbaden, Germany). The assay
detects antibodies to both structural (core region) and non-
structural proteins of the HCV genome with sensitivity and
specificity estimated to be above 99 %. Anti-HCV posi-
tive samples were tested for serum HCV RNA using
Taborelli et al. Infectious Agents and Cancer  (2016) 11:27 Page 2 of 6
the Abbott HCV RealTime (ART, Abbott Diagnostic
Division, Wiesbaden, Germany) with a limit of detection
of 12 IU/mL. Samples were considered HCV-positive if
HCV antibodies and HCV RNA were detected.
HBV
Testing for antibodies to HBV surface antigen (anti-HBs)
and antibodies to HBV core antigen (anti-HBc) was per-
formed using CMIA (ARCHITECT anti-HBs and ARCHI-
TECT anti-HBc, Abbott Diagnostic Division, Wiesbaden,
Germany). Samples giving borderline test results were
retested. HBV surface antigen (HBsAg) was tested using
CMIA (ARCHITECT HBsAg Abbott Diagnostic Division,
Wiesbaden, Germany) and confirmed by neutralization
test (AxSYM, Abbott Diagnostic Division, Wiesbaden,
Germany). Samples were deemed HBsAg+ when posi-
tive at the neutralization test. Study subjects without
available information on all three HBV markers (one
case and seven controls) were excluded from analyses
on HBV markers.
Statistical methods
Adjusted odds ratios (ORs) and corresponding 95 %
confidence intervals (95 % CIs) were estimated by un-
conditional multiple logistic regression, including terms
for matching variables –i.e., gender, age (in quinquennia
plus a term for age as a continuous variable), study cen-
ter– and potential socio-demographic determinants (i.e.,
years of education and place of birth) [16].
Results
Table 1 shows the distribution of NHL cases and con-
trols from both consecutive studies by study center, cal-
endar year, gender, age, place of birth, and education.
People born in southern Italy were at elevated NHL risk
(OR = 2.35, 95 % CI: 1.60–3.47), as compared to those
born in northern or central Italy. Education level was
unrelated to NHL risk.
The association between HCV and HBV serologic
markers and NHL risk is shown in Table 2. Altogether, 79
NHL cases (13.8 %) and 64 controls (6.4 %) were anti-HCV
+ (OR = 2.39, 95 % CI: 1.66–3.43). In the confirmatory ana-
lysis with HCV RNA, 63 NHL patients (11.1 %) and 35
controls (3.5 %) were found positive, leading to a 3.5-fold
higher risk of NHL in people positive for HCV RNA+
(95 % CI: 2.25–5.47) as compared to anti-HCV−. Con-
versely, no excess of NHL risk emerged among anti-HCV
+/HCV RNA− people (OR = 0.98, 95 % CI: 0.50–1.92).
Approximately 60 % of both NHL cases and controls
tested negative for any HBV serologic markers (Table 2).
The prevalence of HBsAg seropositivity was 3.7 %
among NHL cases and 1.7 % among controls, leading to
an OR of 1.95 (95 % CI: 1.00–3.81) for HBsAg+ individ-
uals compared to people susceptible to HBV infection.
Immunity due to natural infection (i.e., HBsAg−/anti-
HBs+/anti-HBc+), immunity due to vaccination (HBsAg-/
anti-HBs+/anti-HBc-), and the positivity for anti-HBc
alone (HBsAg−/anti-HBs−/anti-HBc+) were not signifi-
cantly associated with NHL risk. Chronic co-infection
of HBV and HCV was reported in only one NHL case.
Subgroup analyses of the association between NHL
and the presence of HCV RNA or HBsAg were per-
formed for the main histological subtypes (Table 3). The
prevalence of HCV RNA positivity was 11.7 % among B-
cell NHL subtypes, whereas only two out of 37 (5.4 %)
T-cell NHL cases were found to be positive for HCV
RNA. HCV RNA+ people, as compared to anti-HCV−,
showed an elevated risk of diffuse large B-cell lymphoma
(DLBCL; OR = 4.08, 95 % CI: 2.46–6.76), marginal zone
lymphoma (MZL; OR = 8.62, 95 % CI: 3.43–21.69), lym-
phoplasmacytic lymphoma (LPL, OR = 8.43, 95 % CI:
2.26–31.52), and small lymphocytic lymphoma/chronic
lymphocytic leukemia (SLL/CLL; OR = 7.96, 95 % CI:
2.95–21.48). Regarding HBV, the proportion of HBsAg-
Table 1 Distribution of 571 NHL and 1004 controls with ORs
and 95 % CIs for selected characteristics. Italy, 1999–2014
NHL Controls
N (%) N (%) OR (95 % CI)a
Study center
Aviano 272 (47.6) 527 (52.5)
Napoli 215 (37.7) 359 (35.8)
Catania 84 (14.7) 118 (11.7)
Year of interview
1999–2002 228 (39.9) 504 (50.2)
2003–2014 343 (60.1) 500 (49.8)
Gender
Male 318 (55.7) 622 (62.0)
Female 253 (44.3) 382 (38.0)
Age (years)
<45 137 (24.0) 305 (30.4)
45–64 260 (45.5) 366 (36.4)
≥65 174 (30.5) 333 (33.2)
Place of birthc
North-Center 221 (38.8) 487 (48.6) 1b
South 349 (61.2) 515 (51.4) 2.35 (1.60–3.47)
Education (years)c
<7 195 (34.2) 368 (36.6) 1b
7–11 186 (32.6) 300 (29.9) 1.27 (0.96–1.70)
≥12 189 (33.2) 336 (33.5) 1.20 (0.90–1.60)
NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval
aEstimated using an unconditional logistic regression model adjusted for gender,
age, study center, years of education, and place of birth; bReference category;
cThe sum does not add up to the total because of some missing values
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positive cases was 3.9 % among B-cell NHL and 0.0 %
among T-cell NHL. HBsAg positivity was associated
with a significantly increased risk of B-cell NHL sub-
types overall (OR = 2.11, 95 % CI: 1.07–4.15) and of
DLBCL in particular (OR = 2.69, 95 % CI: 1.30–5.59).
Neither HCV nor HBV infections were significantly as-
sociated with the risk of follicular NHL (FL).
Discussion
The findings from this large case-control study con-
firmed the well-established association between HCV in-
fection and NHL, highlighting the potential favorable
role of prevention and treatment of HCV infection. The
study also provided further evidence on the role of HBV
infection in NHL etiology, reporting a 2-fold signifi-
cantly elevated risk of B-cell NHL in HBsAg+ people. No
increased risk emerged among people immunized be-
cause of past infection or vaccination, or among those
who tested positive for anti-HBc alone.
Although chronic HCV infection has been associated
to NHL since the early 1990s [17, 18], the International
Agency for Research on Cancer definitely linked it to
NHL etiology only in 2009 [3]. These findings were fur-
ther supported by a recent pooled analysis of case-
control studies from the InterLymph Consortium [5],
which reported an 1.8-fold increase in NHL risk for
anti-HCV+ people.
Although anti-HCV-positivity was associated to NHL
risk, we found that only individuals with circulating HCV
RNA were actually at increased risk for NHL, indicating
that only persistent chronic HCV infection is associated
to lymphomagenesis. This finding is in agreement with a
previous large multicenter case-control study from EPI-
LYMPH [19], which found a statistically significant associ-
ation between NHL and detectable HCV RNA (OR = 1.82,
95 % CI: 1.13–2.91).
The association with HCV-positivity was found for a
broad range of B-cell NHL subtypes, with a high
Table 3 ORs and 95 % CIs for selected NHL histological types by HCV RNA/HBsAg positivity. Italy, 1999–2014
Allc HCV-RNA+ Alld HBsAg+
N N (%) OR (95 % CI)a,e N N (%) OR (95 % CI)a,f
Controls 1002 35 (3.5) 1b 997 17 (1.7) 1b
NHL cases 569 63 (11.1) 570 21 (3.7)
B-cell lymphomas 512 60 (11.7) 3.71 (2.37–5.81) 513 20 (3.9) 2.11 (1.07–4.15)
DLBCL 289 37 (12.8) 4.08 (2.46–6.76) 290 15 (5.2) 2.69 (1.30–5.59)
Burkitt 14 2 (14.3) 4.36 (0.82–23.26) 14 0 (0.0)
Follicular 103 1 (1.0) 0.38 (0.05–2.85) 103 4 (3.9) 1.96 (0.61–6.29)
Mantle cell 14 0 (0.0) 14 0 (0.0)
Marginal zone 33 9 (27.3) 8.62 (3.43–21.69) 33 0 (0.0)
Lymphoplasmacytic 14 4 (28.6) 8.43 (2.26–31.52) 14 0 (0.0)
Other B-cell lymphomas 10 0 (0.0) 10 0 (0.0)
SLL/CLL 35 7 (20.0) 7. 96 (2.95–21.48) 35 1 (2.9) 1.18 (0.14–10.05)
T-cell lymphomas 37 2 (5.4) 1.68 (0.37–7.69) 37 0 (0.0)
Other 2 0 (0.0) 2 0 (0.0)
NOS 18 1 (5.6) 1.73 (0.20–15.01) 18 1 (5.5) 2.58 (0.28–23.84)
NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval, DLBCL diffuse large B-cell lymphoma, SLL small lymphocytic lymphoma, CLL chronic lymphocytic
leukemia, NOS not otherwise specified; aEstimated using unconditional logistic regression models adjusted for gender, age, study center, years of education, and place
of birth; bReference category. cCases and controls with positive anti-HCV test and without available information on HCV-RNA were excluded; dCases and controls without
available information on HBV markers were excluded; eReference category was anti-HCV-; fReference category was HBsAg-/anti-HBs-/anti-HBc-
Table 2 ORs and 95 % CIs for NHL by markers of HCV and HBV.
Italy, 1999–2014
NHL Controls
N (%) N (%) OR (95 % CI)a
HCV 571 1004
Anti-HCV- 492 (86.2) 940 (93.6) 1b
Anti-HCV+ 79 (13.8) 64 (6.4) 2.39 (1.66–3.43)
HCV RNA-c 14 (2.5) 27 (2.7) 0.98 (0.50–1.92)
HCV RNA+ 63 (11.1) 35 (3.5) 3.51 (2.25–5.47)
HBVd 570 997
HBsAg-/anti-HBs-/anti-HBc- 359 (63.0) 609 (61.1) 1b
HBsAg-/anti-HBs+/anti-HBc+ 90 (15.8) 179 (18.0) 0.78 (0.58–1.06)
HBsAg-/anti-HBs+/anti-HBc- 53 (9.3) 122 (12.2) 0.87 (0.59–1.29)
HBsAg-/anti-HBs-/anti-HBc+ 47 (8.2) 70 (7.0) 1.10 (0.73–1.65)
HBsAg+ 21 (3.7) 17 (1.7) 1.95 (1.00–3.81)
NHL non-Hodgkin lymphoma, OR odds ratio, CI confidence interval
aEstimated using unconditional logistic regression models adjusted for gender,
age, study center, years of education, and place of birth; bReference category;
cInformation on HCV RNA was missing for 2 cases and 2 controls; d1 case and
7 controls without complete information on all HBV markers were excluded
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prevalence of chronically infected NHL patients (13–
29 %) in our study. Our results are in agreement with
several studies that found an association of HCV with
DLBCL, MZL, LPL, and SLL/CLL [7, 19–24]. At vari-
ance with a previous study [25], no significant associ-
ation emerged between HCV infection and Burkitt
lymphoma. Prior studies have produced mixed results
for T-cell NHL [6], but no significant relationship with
HCV infection emerged from our study.
The association between HCV infection and B-cell NHL
found in this study is consistent with the evidence that
proliferation of specific B-cell clones, caused by chronic
antigenic stimulation induced by HCV, plays a role in the
pathogenesis of B-cell lymphomas [26]. In fact, continuous
stimulation of the immune system by HCV may lead to
molecular alterations in the lymphocytes, immune dysreg-
ulation, and eventually B-cell [27].
HBV infection has been studied less frequently than
HCV infection in relation to NHLs, and most of the evi-
dence is based on case–control studies [3, 9]. Further-
more, although a comprehensive testing of HBV antigens
and antibodies is required to assess the HBV status, only
few studies considered the complete HBV serological
panel. In our study, a two-fold increased NHL risk was
found among HBsAg+ patients. The association was statis-
tically significant for B-cell NHL. A previous Italian study
on B-cell lymphomas [28] reported complete information
on HBV serology, showing a pattern of association be-
tween HBV status and NHL very similar to our present
findings. Conversely, non-significant associations were re-
ported by the Epilymph case-control study [29] for both
chronic and past HBV infections.
The majority of the studies have considered the HBV
markers separately, most of them resting on HBsAg.
Findings on HBsAg+ have been associated to a 1.5-to-4-
fold increase in NHL risk [10, 12, 13, 30, 31]. Seroposi-
tivity to anti-HBc alone has been investigated quite
rarely as a marker of past HBV infection, reporting a
moderate or non-significant association with NHLs [12].
Although our results should be interpreted with cau-
tion as they are based on a relatively small number of
HBV carriers, we found that HBsAg+ patients had an el-
evated risk for B-cell NHL and, particularly, DLBCL. In
agreement with our results, a multicenter case-control
study [28] found a higher prevalence of HBsAg+ among
patients with DLBCL or FL than among controls. In
South Korea, a large cohort study [30] showed that
HBsAg-positivity was associated with an increased risk
of DLBCL, but not with FL.
The association of NHL, and predominantly of B-cell
lymphoid malignancies, with active chronic HBV infection,
though not with past exposure, suggests that HBV might
promote B-cell lymphomagenesis in a way similar to that
proposed for HCV (i.e., chronic antigen stimulation of B-
cells), possibly enhanced by engagement of B-cell surface
receptors and co-stimulatory molecules [6].
The presence of occult HBV infections – i.e., the pres-
ence of circulating HBV DNA in HBsAg−/anti-HBs− pa-
tients – is a relevant concern in etiological studies, since it
may lead to biased results. Occult HBV infection was,
however, rare in our study population. In a companion
study on HCC, all HBsAg−/anti-HBs− cases and controls
were screened for HBV DNA [14]. HBV DNA was de-
tected in one HCC case out of 85 HBsAg−/anti-HBs−/anti-
HBc− study subjects (1.2 %) and in one HCC case out of
36 HBsAg−/anti-HBs−/anti-HBc+ subjects (2.8 %). Both
cases were co-infected with HCV.
Interpretation of study findings should take into account
some limitations. First, hospital-based case-control studies
are prone to selection bias in the inclusion of hospital
controls. However, the prevalence of HBV and HCV posi-
tivity in the control group was consistent with the findings
of previous surveys of hepatitis virus prevalence in Italy
[32]. Furthermore, individuals admitted to hospital for dis-
eases related to alcohol and tobacco consumption, or
hepatitis viruses and autoimmune diseases, were excluded.
Second, despite the relatively large sample size, the study
has still limited power to detect association for specific
NHL subtypes. Third, people with anti-HCV− were not
tested for HCV RNA. Although an underestimation of
HCV prevalence cannot be completely ruled out, no ex-
cess of NHL risk emerged among anti-HCV+/HCV RNA−
people. Accurate testing for serological detection of HCV/
HBV in a centralized laboratory and the revision of NHL
diagnosis represent important strengths of our study.
Conclusions
Our case-control study confirmed the association be-
tween HCV infection and risk of NHL, including the
major NHL subtypes. Furthermore, our results lent add-
itional support to the possibility that chronic HBV infec-
tion may also have a role in the development of B-cell
NHL. Prevention and treatment of HCV and HBV infec-
tion is increasingly possible and may diminish NHL inci-
dence, notably in areas with high prevalence of infection
with hepatitis viruses.
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